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Abstract
The COVID-19 pandemic is sweeping the world and will feature prominently in all our lives for months and most
likely for years to come. We review here the current state 6 months into the declared pandemic. Specifically, we
examine the role of the pathogen, the host and the environment along with the possible role of diabetes. We also
firmly believe that the pandemic has shown an extraordinary light on national and international politicians whom
we should hold to account as performance has been uneven. We also call explicitly on competent leadership of
international organizations, specifically the WHO, UN and EU, informed by science. Finally, we also condense
successful strategies for dealing with the current COVID-19 pandemic in democratic countries into a developing
pandemic playbook and chart a way forward into the future. This is useful in the current COVID-19 pandemic and,
we hope, in a very distant future again when another pandemic might arise.
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Introduction
COVID-19 is an infectious disease caused by the severe
acute respiratory syndrome coronavirus 2 [1]. It is currently
sweeping the world almost a year on. Furthermore, it will be
an enduring feature of our lives.
The COVID-19 pandemic was declared by the WHO
on 11/3/2020 [2], although some countries acted sooner,
for example, Australia on 24/2/2020 [3]. Therefore, we call
explicitly for the examination the actions of politicians in
selected countries and international organizations.
We here take stock of the current situation 6 months
into the pandemic and attempt to consider the future,
including relevant questions to be answered. Routes of
SARS-CoV-2 transmission has been an active area of re-
search. We discuss the prevalent modes, including the
emergence of airborne transmission. Furthermore, we
highlight the contribution of asymptomatic transmission
of SARS-CoV-2 as a major challenge in controlling the
spread of COVID-19 [4, 5].
Main text
The pathogen, host and the route of virus transmission
“Knowledge is a weapon. Gear up well before going into
battle”, says Game of Thrones writer, George R.R.
Martin. A pandemic infection such as that from SARS-
CoV-2 must be fought with the weapons of knowledge:
only now, after 6 months from the epidemic that has be-
come a pandemic, do we have knowledge that can be
useful to win not the battle, but the war against the
SARS-CoV-2 coronavirus.
We note here that a most helpful timeline of research
into COVID-19 was recently published [6]. We refer our
readers to this paper rather than recapitulating the time-
line here.
We will be organizing our thoughts around a series of
articles to provide research advances on three important
aspects of the pandemic:
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3. The routes of virus transmission
The pathogen
The origin and direct ancestral viruses of SARS-CoV-2
have not been identified, but it is probably a novel re-
combinant virus [7]. Its genome is indeed closest overall
(96.2% similarity) to SARSr-Ra-BatCoV-RaTG13 from
horseshoe bats (Rhinolophus affinis) that had been col-
lected in Pu'er, Yunnan, China, in 2013 [8]; however, its
receptor-binding domain (RBD) is closest to that of from
smuggled pangolins in Guangzhou (pangolin-SARSr-
CoV/MP789/Guangdong/2019). However, there might
be one or more unidentified (probably bat) virus(es) with
a nearly identical RBD to that of SARS-CoV-2 and pan-
golin SARSr-CoV. There are eight species of pangolins
in the mammalian order of Pholidota which is most
closely related to Carnivora (cat-like and dog-like carni-
vorans). All are insectivorous and toothless animals
whose body is largely covered by keratinous scales. The
human receptor for SARS-CoV-2, angiotensin I-
converting enzyme 2 (ACE2), is conserved in pangolins,
and coronaviruses isolated from pangolins have a
receptor-binding domain in their spike protein that is
uniquely similar to that of SARS-CoV-2. Interestingly,
pangolins have lost IFIH1 (interferon induced with heli-
case C domain 1) and ZBP1 (Z-DNA binding protein 1)
genes during evolutionary divergence. IFIH1 and ZBP1
proteins are intracellular sensors of exogeneous RNAs
able to activate cellular and organismal responses, such
as necroptotic cell death, interferon signaling and in-
flammation [9]. It is possible that the loss of the IFIH1
and ZBP1 genes provided an evolutionary advantage by
reducing the inflammation-induced damage to the host
tissues and thus contributed to the transition from re-
sistance to tolerance of viral infections in pangolins [9].
This hypothesis, if confirmed, could be the basis of the
phenomenon of viral accommodation in some species.
However, although there are indications of the role that
the pangolin could play in the spread of SARS-CoV-2,
there is no direct evidence (experimental infection) that
this animal is the intermediate host of the virus [10].
The virus was fairly stable (without significant muta-
tion) until 01/12/2020, and spread through human con-
tact, and not from its inherent abilities for rapid growth
and continuous evolution. Although 230,000 viral gen-
omic sequences of hCoV-19 have been submitted and
shared in GISAID [11], few mutations of any clinical sig-
nificance have been identified thus far. A missense mu-
tation, D614G, in the spike protein of SARS-CoV-2,
predominant in Europe (954 of 1449 (66%) sequences)
which is now spreading worldwide (1237 of 2795 (44%)
sequences), seems to cause a higher infection rates
in vitro [12, 13]. However, the lack of detailed clinical
data suggests that probably this mutation is neutral. Re-
cently, a novel recurrent mutation has been identified in
Singapore and other countries, Δ382 variant, that seems
to be associated with a milder infection [14]. Many other
mutations have been identified and described, but none
of these to date are associated with increased viral trans-
mission. It is possible that the recurrent mutations iden-
tified are induced by host immunity through RNA
modification mechanisms and probably tend to be se-
lectively neutral, with no or negligible effects on the
transmissibility of the virus [15]. Paradoxically, it
could be argued that SARS-CoV-2’s low genetic diver-
sity results in an advantage for mass vaccine
immunization [16].
The host
The vast majority of infections are asymptomatic or
mildly symptomatic, while deaths account for < 1% of in-
fected cases. We know for certain that age is a risk fac-
tor—the death rate from COVID-19 soars for patients
over the age of 60. This is true of many infections and
generally is related to a deficiency in the immune system
and pre-existing health conditions. Children are less
prone to develop severe COVID-19 [17]. These differ-
ences are certainly attributable to the genetic diversity of
the host. The scientific literature begins to give us infor-
mation on these differences concerning the individual
and gender production of hormones, differential T cell
response (women produce more T cells compared to
males), the expression of specific genes that increase or
decrease their activity when the virus enters and leaves
our cells, the diversity of blood groups (group A seems
to increase the risk, while group 0 subjects have a lower
risk of getting sick), the genes that produce our anti-
bodies and all the defense mechanisms, as well as some
genes of susceptibility to cardiovascular disease, seem to
favor the severity of the disease [18, 19]. Similarly, sig-
nificant association were found for HLA alleles (HLA
B*27:07, DRB1*15:01, DQB1*06:02) [20]. Numerous can-
didate genes have now been analyzed for searching sus-
ceptibility and/or resistance alleles. Much attention has
been directed to the genes that encode SARS-CoV-2 cel-
lular entry proteins. Indeed, coronavirus entry into host
cells is an important determinant of viral infectivity and
pathogenesis and is an important target for host immune
surveillance and therapeutic strategies [21–23]. How-
ever, none of these genes showed susceptibility and/or
resistance alleles. Much attention has been directed to-
wards the ACE2 receptor which has proved to be min-
imally variable and probably intolerable towards
mutations with loss of function. It is possible, consider-
ing the role of ACE2 in the pathogenesis of the disease,
that differences are to be found in the genes that
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regulate the expression of ACE2 [24]. In fact, ACE2 is
expressed in many organ tissues involving vital and crit-
ical systems such as the respiratory, immunological, vas-
cular, renal-excretory, cardiac, reproductive and nervous
systems [25]. The omnipresence of ACE2 demonstrates
that SARS-CoV-2 has developed an extraordinary evolu-
tionary strategy to guarantee its replication, survival and
diffusion by exploiting a very common transmembrane
protein, abundant and capable of altering physiological
processes in a simultaneous way.
Our genes can influence how our immune systems re-
spond to an infection, which could explain why some
people have more severe symptoms of the disease and
others are asymptomatic. It is possible that a sort of
“viral accommodation”, a phenomenon well known in
plants and animals, exists also for coronaviruses [26].
Viral accommodation (or disease tolerance) is the ability
of an individual, due to a genetic predisposition or cer-
tain behavioral (lifestyle) aspects, to thrive despite being
infected with a pathogen that causes disease in a popula-
tion. This is different from resistance because in this
case, the infection is eliminated by the immune system
or by other defensive molecules. Deciphering the mo-
lecular mechanisms of viral accommodation is important
for identifying asymptomatic people and for developing
drug therapies for COVID-19. To date, no specific gen-
omic biomarkers have emerged to be used to identify
subjects or groups belonging to the different risk classes
and above all to be used in the prognosis and monitor-
ing of therapies. It is certain that the consequences of
SARS-CoV-2 internalization are regulated by a complex
and largely unknown network of host-pathogen interac-
tions, in which viral and host genomic variability can de-
limit the final outcome of the infection. For instance,
little is known regarding the interaction of individual
SARS-CoV-2 proteins and RNA with the host interferon
(IFN) and inflammatory responses, even though such in-
teractions can determine the fate and/or efficiency of in-
fection, transmission, and epidemic potential of the
virus. Interestingly, it was recently [27] discovered that
individuals carrying germinal mutations in genes active
in toll-like receptor 7 (TLR7) among young men with se-
vere COVID-19 confirming an important role of type I
and II IFN responses in the pathogenesis of COVID-19.
This was recently supported by a study of the inter-
national consortium COVID Human Genetic Effort
(covidhge.com) which revealed the presence of loss-of-
function (pLOF) mutations in 13 protein-coding genes
of the interferon pathway. These mutations were found
in 3.5% of patients with severe disease [28]. Functional
deficiency of these genes during infection greatly reduces
or limits the production of type I interferon molecules.
This genetic study was also reinforced by a second art-
icle from the same consortium which revealed that other
severe patients have autoantibodies against interferon I
for a genetic mechanism not yet identified, but which
highlights the role of interferon and its receptors in the
pathogenesis of severe forms of COVID-19 [29].
Despite the many unknowns that remain, there has
been notable progress made towards understanding how
SARS-CoV-2 spreads and infects the human host. Data
reveals that the hospitalizations and deaths attributable
to COVID-19 follow patterns based on a variety of fac-
tors. For instance, COVID-19 mortality data in the USA
indicates that about 70% of deaths occurred in patients
older than 70 years of age [30]. In addition to age, there
is clear evidence that pre-existing conditions affect mor-
tality and disease severity. Among the most prominent
risk factors are a medical history of hypertension, dia-
betes and cardiovascular disease [31]. Diabetes is one co-
morbidity that is especially concerning because of the
increasing prevalence of diabetes worldwide [32]. Data
thus far supports the troubling link between diabetes
and COVID-19. In a summary report of over 72,000 pa-
tients, the Chinese CDC found an overall case fatality
rate of 2.3% which increases to 7.3% in diabetic patients
[33]. One study showed that 8% of hospitalized patients
were diabetic, but this percentage increases to 22% of
ICU patients [34]. Furthermore, a recent meta-analysis
of 21 clinical studies has shown evidence that diabetes is
associated with disease severity, with the percentage of
critical cases in diabetes being 44.5 % [35].
Despite an understanding of the linkage between pre-
existing comorbidities and clinical outcomes, there is
still much debate about the ways diabetes can impact
disease severity [36]. It is known that the ACE2 receptor
facilitates viral entry into the cell [22]. The binding of
SARS-CoV-2 to the ACE2 receptor is notable because of
the expression of the receptor in the islets of the pan-
creas [37]. This binding may inflict permanent damage
upon the beta cells within the islet which is a cause for
concern because healthy beta cells act as a central com-
ponent of proper insulin secretion [38]. Beta cells are
crucially important and permanently altering them is
directly related to disease pathogenesis of diabetes and
may be a factor in the development of post SARS-CoV-2
diabetes that has been reported in some patients thus far
[39]. In addition to damage through direct binding, gly-
cemic control is another important aspect to consider
when looking at COVID-19 severity in diabetic patients;
it has been shown that improved glycemic control is cor-
related to better patient outcomes [40]. Another factor
that must be considered in diabetic patients is the down-
stream effects of SARS-CoV-2 binding at the ACE2 re-
ceptor. The local renin angiotensin system is of upmost
importance in the pancreas for controlling insulin secre-
tion and the ACE2 receptor is directly implicated in this
system [41]. Normally, the ACE2 receptor facilitates the
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transition of AngII to Ang [42] which is important in
maintaining balance of oxidative stress within the cell,
but when SARS-CoV-2 is bound, it is unclear as to what
capacity this conversion occurs [42]. While the true
mechanism behind diabetes and disease severity is still
unclear, what is clear is the importance of this area of
developing research. Furthermore, the development of
diabetes after a viral infection is not unprecedented. In-
deed, when looking at past human coronaviruses such as
SARS, there have also been reports of the development
of diabetes [43].
The routes of virus transmission
SARS-CoV-2 is a respiratory virus with transmission
widely accepted to occur between people in close con-
tact, primarily through droplets expelled through various
respiratory activities, such as coughing, sneezing, singing,
and talking [44, 45]. There has been considerable re-
search conducted over the past 6 months exploring the
contribution of other routes of transmission to the
spread of this infectious disease. Early in the pandemic,
SARS-CoV-2 was demonstrated to be remain viable on
surfaces for extended periods, ranging from 4 h to longer
than 48 h, depending on the material [46]. More recent
studies have suggested that risk of fomite transmission
from inanimate objects is unclear [47]. Virus can also be
found in various bodily fluids, including stool, blood,
semen and ocular secretions [48]. The role of contact with
these fluids in risk of transmission has yet been reported.
Considerable epidemiological evidence has emerged dem-
onstrating SARS-CoV-2 can be transmitted through the
air [49, 50]. Understanding prevalent transmission routes
shapes the control measures that are required to prevent
and control infection with SARS-CoV-2. Acknowledge-
ment of airborne SARS-CoV-2 transmission through in-
haled aerosols was initially met with resistance by the
WHO [51]. Part of the challenge in gaining recognition of
this transmission mode was in [1] gathering sufficient evi-
dence of detection of SARS-CoV-2 in the air, [2] demon-
stration of viability of viral material from air samples, and
[3] further linking exposure of viable airborne SARS-CoV-
2 with infection of COVID-19. While SARS-CoV-2 was
reported in air samples collected from hospital locations
and some public locations early in the pandemic (April
2020), the sampling techniques by these studies were not
conducive to preserving the lipid envelope of the virus
[52]. Development of air sampling technologies which col-
lect airborne material into an aqueous media has enabled
the viability of SARS-CoV-2 in air samples to be demon-
strated [53]. Application of improved exposure measure-
ment technology in different environments will allow for
the dynamic nature of SARS-CoV-2-laden aerosols to be
explored and high-risk settings to be identified.
Inhalation of SARS-CoV-2-laden aerosols is increas-
ingly being recognized as a relevant transmission mode.
The role of aerosols in the spread of COVID-19 is sup-
ported by [1] the range of respiratory activities, from
breathing to speaking to singing, that produce aerosol
and [2] the large number of cases that involve asymp-
tomatic or pre-symptomatic individuals. Questions
remain regarding the mechanisms by which aerosols are
produced that lead to variability between individuals (i.e.
airway geometrics between adults and children, respira-
tory tract fluid viscosities, stage/location of infection).
Epidemiological studies reporting COVID-19 outbreaks
have commonly occurred in indoor environments
(Nishiura H, Oshitani H, Kobayashi T, Saito T, Sunagawa
T, Matsui T, et al: Closed environments facilitate second-
ary transmission of coronavirus disease 2019 (COVID-19),
unpublished). As communities look to safely reopening,
we can consider the characteristics of these enclosed
spaces as well as the behaviors of individuals occupying
these spaces to minimize the risks associated with air-
borne transmission. Control of expelled aerosol at the
source (i.e. mouth/nose of infected individuals) by wearing
face coverings (masks) is an important strategy for redu-
cing transmission. Virus-laden aerosol can remain sus-
pended in the air for hours and be easily transported some
distance away from infected individuals. Aerosol concen-
trations in indoor spaces can be effectively lowered
through properly ventilation (i.e. use of outdoor air, high
air changes) and filtration of recirculated air. Ultimately,
these strategies aimed at airborne transmission should be
layered together with the fundamental principles of dis-
ease control (i.e. physical distancing, hand hygiene) when
developing a safe and comprehensive plan for limiting
community transmission of COVID-19.
Therapies
Since the pandemic broke out, international research la-
boratories, together with pharmaceutical companies and
biotech companies, are working in an unprecedented
manner at extraordinary rates to find and evaluate drugs,
vaccines and other solutions aimed at decreasing hos-
pital admissions and to help heal patients and support
recovery. Regulatory agencies worldwide (EMA, FDA,
PMDA) have been increasingly enriched with new trials
against the disease caused by the SARS-CoV-2 virus.
Antiviral drugs are being studied, aimed at inhibiting the
replication of the virus; immunomodulatory drugs, to
attenuate the overactive immune system; neutralizing
antibodies, to inhibit the virus and help the immune sys-
tem clear the infection; and passive immunization with
convalescent serum which contains a wide range of anti-
bodies, cytokines and other immunomodulators. Dozens
of “repurposed” drug candidates (most notably, anti-
retroviral protease inhibitors approved for the treatment
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of HIV) are still being evaluated in hundreds of trials
around the world [54]. Many have been eliminated be-
cause they are ineffective. Remdesivir, on the other hand,
currently seems to be the only treatment at the moment
with some effectiveness against COVID-19 (albeit with
not striking results) [55]. Recently, British colleagues
have shown that dexamethasone, a steroid anti-
inflammatory, is effective in severely infected patients
who develop a systemic inflammatory response resulting
in lung injury and dysfunction of other organs [56].
However, this drug cannot be used for all patients, who
may indeed have very serious adverse events. As for the
immunomodulator, tocilizumab, the results are mixed
and it is necessary to await further evaluations. There is
much discussion on the possibility of using the plasma
of convalescents, which is the plasma that is collected
from subjects exposed to the virus and who have devel-
oped antibodies following the resolution of the infection.
Passive administration of these antibodies via convales-
cent plasma transfusion may be a short-term strategy to
confer immediate immunity to sensitive individuals.
Convalescent plasma has been used successfully in the
past as post-exposure prophylaxis and in the therapeutic
treatment of other coronavirus outbreaks (e.g. SARS-1
and MERS-CoV]) and other autoimmune and chronic
inflammatory diseases, such as dermatomyositis,
Kawasaki disease, multiple sclerosis, lupus, chronic
lymphocytic leukemia, and idiopathic thrombocytopenic
purpura. Convalescent plasma has also been used in the
COVID-19 pandemic in a few published cases in China,
Italy and other countries with some clinical benefits doc-
umented at radiological, laboratory level and improved
survival [34]. Nevertheless, these experiences suggest
that we need further studies characterized by a
standardization of quality and quantity of antibodies. In
fact, [57] demonstrated that (a) individuals with mild
and severe disease produced neutralizing IgG to SARS-
CoV-2 10 days after disease onset, (b) SARS-CoV-2 per-
sisted longer in those with severe disease, and (c) there
was cross-reactivity between antibodies to SARS-CoV-1
and SARS-CoV-2, but only antibodies from patients with
COVID-19 neutralized SARS-CoV-2. Not very different
is the idea of using, for passive immunization, monoclo-
nal antibodies (Mabs) obtained in the laboratory instead
of the plasma of convalescent subjects [58]. Monoclonal
antibodies are specifically addressed to block the spike
protein of the virus in order to block its binding with
the ACE2. Mabs are preferred because of their specifi-
city, purity, low risk of blood pathogen contamination,
and safety over convalescent plasma therapy. Passive ad-
ministration of monoclonal antibodies could have a
major impact on the control of the SARS-CoV-2 pan-
demic by providing immediate protection, complement-
ing the development of prophylactic vaccines. There are
at least 15 groups in the world active in the identifica-
tion and production of monoclonal antibodies against
SARS-CoV-2. The passive infusion of Mabs can be used
as pre-exposure or post-exposure prophylaxis and offer
immediate protection against infection that could last
weeks or months. Even if a vaccine will be available, the
weeks to generate an effective immune response empha-
sizes the benefits of passive immunity from Mabs in a
variety of circumstances including, for example, health-
care settings such as hospitals and nursing homes, or
health centers, high risk industries or cruise ships.
Currently, there is no single specific vaccine or ef-
fective antiviral therapy against SARS-CoV-2. Com-
panies at work estimate that this vaccine will take
years to develop and test before reaching a large
population [59]. There are currently over 200 differ-
ent candidate vaccines being studied, none of them
have yet proved effective and safe. Recently, at least
10 companies announced the first data from their
phase 3 studies of vaccine candidates with promising
and interesting results. Some of these companies have
begun the data evaluation process at the Food and
Drug Administration (USA) and European Medicine
Agency (EMA) [60]. However, it is important that
pharmaceutical companies who have announced data
on their vaccines in press releases provide the scien-
tific community with the results as soon as possible
through publication in peer-reviewed journals. The
world looks forward to this data, and we will review
progress on this front in due course when full peer-
reviewed data becomes available. We all deserve
transparency in our search for safe and effective vac-
cines. Interestingly, two novel candidate vaccines
based on mRNA which encode a secreted SARS-CoV-
2 receptor-binding domain encapsulated in lipid
nanoparticles have been obtained [61]. The manufac-
turers of these vaccines (Moderna and Pfizer) have
announced that their vaccines would have between 90
and 95% efficacy. But it is necessary to proceed with
caution at least until phase 3 is concluded. In
addition, it will be non-trivial to reach some popula-
tions since these vaccines are RNA-based and hence
need low temperature storage.
On 11 and 18 December, respectively, the FDA autho-
rized the administration of the Pfizer / BioNTech and
Moderna vaccines.
Having no vaccines or targeted therapies yet, effective
solutions are quickly needed, also in consideration of the
economic and social recovery phase, and to allow hospi-
tals to operate at full capacity. To win this war on a glo-
bal level, the answer must be global: the responsibility of
the individual in adopting precautionary behaviors must
be combined with consistent indications, cooperation
between institutions, circulation of knowledge and
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strong signs of support for research because the answer
can only be found by searching for it thoroughly.
A pandemic playbook
The COVID-19 pandemic has led to various strategies to
prevent and contain its spread. We condense here strategies
from Western democracies into a playbook which may be
useful now and in the future. Western democracies have
expectations of civil liberties that must be weighed against
the common good in an emergency situation.
We take particular note of Mike Ryan’s (of the WHO)
suggestion to “go hard and go early” [62] which appears
to be particularly useful. Furthermore, we must learn to
live with the COVID-19 pandemic for now.
We propose here a pandemic playbook for both early
and less severe stages designed to limit community trans-
mission in earliest stages to control COVID-19 and future
pandemics (Table 1), as well as more drastic action re-
quired for more severe stages (Table 2). Ultimately, in ei-
ther scenario, the virus must be controlled. Public health
still has a useful tool to manage and organize response
strategies to pandemics: the reproduction number, R0,
which provides the average number of new cases of a dis-
ease arising from a single case. Its simple mathematical
power is still relevant today [63].
Reopening societies, economies and countries safely
after the COVID-19 and other pandemics is also a great
challenge. It must avoid additional waves while allowing
a return to normality perhaps with some restrictions.
Clearly there are great physical, mental and economic
benefits. We believe that definitive statements on suc-
cesses cannot yet be made at this point in time, espe-
cially for democracies. However, the situation in Europe
was recently reviewed [64]. In any case, we attempt to
collate some suggestions in Table 3 for this and future
Table 1 The Pandemic Playbook I: leaders must act decisively
and early, informed by science
The Pandemic Playbook I: leaders must act decisively and early,
informed by science
Close borders as quickly as possible
Isolate incoming travellers in supervised quarantine
Require physical distancing
Encourage good hygiene, e.g. frequent hand washing, use of alcohol
hand sanitizers as an alternative, cough etiquette like coughing and
sneezing into a disposable tissue etc., as warranted
Test quickly, rigorously and widely
Deliver test results as quickly as possible, ideally in 24–48 h, to advise
affected individuals, contacts etc. in a timely fashion
Contact trace every case and require close contacts to self-isolate (or
quarantine if advisable)
Take care of the most vulnerable, e.g. in aged care by restricting access
Limit gatherings, to 10 or the like, as the situation dictates
Consider limiting transportation, domestic borders etc.
Communicate clearly, age-appropriately and addressing ethnic and
other minority groups appropriately
Prepare (and possibly expand) hospital facilities, incl. beds, ICUs, staffing
for a possible onslaught of severely affected patients
Be prepared for the unexpected
Table 2 The Pandemic Playbook II: during a (raging) pandemic
The Pandemic Playbook II:
During a (raging) pandemic
Leaders must continue to act decisively and early, informed by science
Test quickly, rigorously and widely
Maintain quick turn-around on test results
Contact trace as effectively as possible, incl. using of technology (such
as a tracing app)
Close contacts must self-isolate if not quarantine
Enforce self-isolation, e.g. through door knocking repeatedly, and con-
sider supervised quarantine if need be
Restrict movement, e.g. to 5 km in cities, 20 km in suburbia, 50 km in
the country
Rigorously ring fence hot spots, if feasible, incl. local and other domestic
borders
Transport, except for essential business, must be limited
Require social distancing (Table 1)
Limit gatherings, to 2 or the like as the situation dictates
Allow only essential business to stay open, incl. supermarkets,
pharmacies, doctors and the like
Limit trips outside the home for food, healthcare or the like each day
within a prescribed radius and to 1x/d
Require protective equipment as warranted, e.g. appropriate face
coverings
Advise of the need for proper hygiene (Table 1)
Communicate clearly, age-appropriate and addressing ethnic groups
appropriately
Ensure the best possible care for the most vulnerable
Manage hospital capacity wisely, incl. staff (which may fall sick), beds,
ICU etc.
Be on the lookout for the unexpected and unexplained
In more dire circumstances,
consider also:
Curfews
Isolation of cases and perhaps contacts
etc. (e.g. on islands)
Table 3 The Pandemic Playbook III: reopening
The Pandemic Playbook III:
Reopening
Reopen cautiously with a measured and careful approach
Continue testing rigorously and widely
Ringfence as soon as necessary if localized outbreaks are documented
Be prepared for the unexpected
Vaccinate widely if possible
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pandemics. The virus must be contained, suppressed if
not eliminated at this stage.
Conclusions: outlook in context, including the
political landscape
The COVID-19 pandemic will hopefully pass in a couple
of years [65]. In the short term, we should learn to live
safely with the disease and specifically do what is neces-
sary to minimize harm due to COVID-19 each one of us
and as a society. Next, in the medium term, we will
hopefully have a vaccine which must be accessible to all
people of this planet. Additionally, we may develop im-
proved treatments for COVID patients which would be
another weapon in fighting the pandemic. We should
also learn the necessary epidemiologic, medical, scien-
tific and political lessons. Clearly, we can also not neg-
lect other health conditions that require medical
attention [66].
Beyond that, we should hold our politicians to ac-
count. Scientific research and medical practice will con-
tribute throughout with essential information and
hopefully treatments and vaccines along with novel bio-
logical, epidemiologic, medical and other insights. As
noted and in due time, we must hold politicians ac-
countable for their actions. In Western democracies, we
can and should do so at the ballot box. Furthermore, we
should also hold international organizations, and their
nowadays mostly political leaders, funded by us tax-
payers, to account to us, the taxpayers funding their ac-
tions. Holding national and local public officials is our
privilege as citizens we must exercise it in these challen-
ging times. Advising, when called upon, is our duty as
citizen-scientists.
Functioning international organizations with expert
leadership taking in scientific advice are key. Unfortu-
nately, many of these organizations are influenced by
geopolitical interests that often delay or prevent rapid
and effective intervention as is required in a pandemic.
The sudden appearance of a new pathogen has
highlighted some critical issues, weak links in the struc-
ture of our society that have contributed to making us
vulnerable to the pandemic. In fact, during the COVID-
19 emergency, the problem of determining an orderly
and clear structure of the competences of the bodies was
proposed, with heavy implications on the management
system of health plans in the various countries and on
that of a more purely legal nature—central, regional or
decentralized administration—deputies to safeguard and
guarantee the fundamental right to health. This was also
evident initially in Wuhan, Hubei province, where the
pandemic originated, in central mainland China. Delays,
accountability and improvisation have unfortunately fa-
vored an emerging epidemic becoming the first pan-
demic of the twenty-first century.
It is clear that from this experience that we must all
commit ourselves to reaping benefits for the future,
avoiding the repetition of mistakes and relying on tech-
nical and scientific skills. In fact, it is appropriate that
the whole system of health institutions can outline strat-
egies aimed at a long-term control of COVID-19, strat-
egies based on innovative methods useful for estimating
and stratifying the susceptibility to the risk of infections.
The shared purpose, the one to which every subject
called in these months to offer their contribution aims,
is the prevention of the impact of pandemics—the
current one and others possibly the future ones—and
more immediately to trust in science and medical prac-
tice to have a short drugs and vaccines capable of neu-
tralizing SARS-CoV-2, responsible for COVID-19.
Finally, we plan to prepare timely updates on the
COVID-19 pandemic for publication in this journal
probably with the next 1 year into the current COVID-
19 pandemic.
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